Cardiac toxicity of trastuzumab: Experience at the Ghent University Hospital, Belgium

Acta Clinica Belgica

Volumn 65, Issue 5, 2010, Pages 300-304

  Lamot, Caroline ^a   Rottey, S ^a,b   De Backer, T ^a,b   Van Bortel, L ^a,b   Robays, H ^a   Van Belle, S ^a   Denys, H ^a   Cocquyt, V ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Breast cancer; Cardiac toxicity; Left ventricular function; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; BELGIUM; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HEALTH INSURANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTIPLE CYCLE TREATMENT; TRICUSPID VALVE DISEASE;

EID: 78149399425     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2010.066     Document Type: Article

References (17)

1. Gschwind A, Fischer OM, Ullrich A, et al. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70 (Pubitemid 38579482)
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82
3. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (abstract). J Clin Oncol 2007; 25:6
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84.
5. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92. (Pubitemid 32222155)
7. Tan-Chiu E, Yothers G, Romond EH, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23:7811-9.
8. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
9. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-329
10. Hershman DL, Shao T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology 2009; 23: 227-34
11. Jones LW, Haykowsky M, Peddle CJ, et al. Cardiovascular risk profile of patients with HER2/neu positive breast cancer treated with anthracycline-taxane- containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev 2007; 16: 1026-31 (Pubitemid 46910108)
12. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab related regimes in HER2 overexpressing Breast Cancer. Clinical Breast Cancer 2007; 7: 600-7
13. Telli ML, Hunt SA, Carison RW, Guardino AE. Trastuzumab related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007; 25: 3525-33
14. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-6
15. Cheitlin M, Armstrong W, Aurigemma G, et al. ACC/AHA/ASE guideline Update for the clinical application of echocardiography: summary article: a report of the American College of cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2003; 108: 1146
16. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiog 2006; 7: 141-6.
17. M Galderisi, F Marra, R Esposito, et al. Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography. Cardiovascular Ultrasound 2007; 5: 1-14